An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis
- 14 June 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (12), 3038-3047
- https://doi.org/10.1158/0008-5472.can-11-3135
Abstract
Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than β-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+/ATP depletion that stimulate Ca2+–dependent programmed necrosis, unique to this new class of NQO1 “bioactivated” drugs. Short-term exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1− cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with β-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to β-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers. Cancer Res; 72(12); 3038–47. ©2012 AACR.Keywords
Other Versions
This publication has 26 references indexed in Scilit:
- β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer TherapyCancer Research, 2010
- Upregulation of NAD(P)H:Quinone Oxidoreductase By Radiation Potentiates the Effect of Bioreductive β-Lapachone on Cancer CellsNeoplasia, 2007
- An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachoneProceedings of the National Academy of Sciences of the United States of America, 2007
- Calcium-dependent Modulation of Poly(ADP-ribose) Polymerase-1 Alters Cellular Metabolism and DNA RepairJournal of Biological Chemistry, 2006
- Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancerMolecular Carcinogenesis, 2005
- NAD(P)H:Quinone Oxidoreductase 1 (NQO1, DT-Diaphorase), Functions and PharmacogeneticsMethods in enzymology, 2004
- NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone CytotoxicityJournal of Biological Chemistry, 2000
- Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.1998
- Immunological Quantitation of DT‐Diaphorase in Carcinoma Cell Lines and Clinical Colon Cancers: Advanced Tumors Express Greater Levels of DT‐DiaphoraseJapanese Journal of Cancer Research, 1998
- Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.1983